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Background:Miro is a mitochondrial protein involved in mitochondrial trafficking.
Results: Mitochondrial damage drives rapid Miro ubiquitination in a manner dependent on Ser-65 in Parkin; however, Miro
degradation is delayed.
Conclusion: Ubiquitination of Miro, rather than its degradation, could act as a signal for mitochondrial arrest and clearance.
Significance: Disruption of the mitochondrial transport machinery could be implicated in Parkinson disease.
Mitochondrial transport plays an important role in matching
mitochondrial distribution to localized energy production and
calcium buffering requirements. Here, we demonstrate that
Miro1, an outer mitochondrial membrane (OMM) protein cru-
cial for the regulation ofmitochondrial trafficking and distribu-
tion, is a substrate of the PINK1/Parkin mitochondrial quality
control system in human dopaminergic neuroblastoma cells.
Moreover, Miro1 turnover on damaged mitochondria is altered
in Parkinson disease (PD) patient-derived fibroblasts contain-
ing a pathogenic mutation in the PARK2 gene (encoding Par-
kin). By analyzing the kinetics of Miro1 ubiquitination, we fur-
ther demonstrate that mitochondrial damage triggers rapid
(within minutes) and persistent Lys-27-type ubiquitination of
Miro1 on the OMM, dependent on PINK1 and Parkin. Protea-
somal degradation of Miro1 is then seen on a slower time scale,
within 2–3 h of the onset of ubiquitination. We findMiro ubiq-
uitination in dopaminergic neuroblastoma cells is independent
of Miro1 phosphorylation at Ser-156 but is dependent on the
recently identified Ser-65 residue within Parkin that is phos-
phorylated by PINK1. Interestingly, we find that Miro1 can sta-
bilize phospho-mutant versions of Parkin on the OMM, sug-
gesting that Miro is also part of a Parkin receptor complex.
Moreover, we demonstrate that Ser-65 in Parkin is critical for
regulating Miro levels upon mitochondrial damage in rodent
cortical neurons.Our results provide new insights into the ubiq-
uitination-dependent regulation of the Miro-mediated mito-
chondrial transport machinery by PINK1/Parkin and also sug-
gest that disruption of this regulation may be implicated in
Parkinson disease pathogenesis.
Mitochondrial transport plays an important role inmatching
mitochondrial distribution to localized energy demand and cal-
cium buffering requirements.Miro1 andMiro2 are outermito-
chondrial membrane (OMM)8 proteins that are crucial for reg-
ulating mitochondrial trafficking and distribution by coupling
mitochondria to the kinesin- and dynein-dependent microtu-
bule transport pathway (1–5). In addition to trafficking, an
accurate mitochondrial quality control system is needed to
degrade damaged mitochondria that can no longer sustain the
cell’s metabolic requirements. PINK1 (PTEN-induced putative
kinase 1; PARK6) and Parkin (PARK2) are components of a
mitochondrial quality control apparatus that promotes the
selective turnover of damaged mitochondria. Loss of function
mutations in PINK1 and Parkin are also associated with rare
recessive forms of PD (6). PINK1, a mitochondrial serine/thre-
onine kinase normally imported into the mitochondrion and
cleaved at the innermitochondrialmembrane, selectively accu-
mulates in its full-length form on the OMM of damaged mito-
chondria and recruits Parkin, an E3 ubiquitin ligase, from the
cytosol to ubiquitinate various OMM substrates (7–12). The
ubiquitination by Parkin of OMM proteins is a crucial step in
the clearance of damaged mitochondria by mitophagy, and
there has been great interest in identifying the mitochondrial
Parkin substrates and receptors of thismitochondrial clearance
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pathway. Several substrates have been identified, including
VDAC1, Mitofusins 1 and 2 (Mfn1 and Mfn2), Drp1, Tom20,
andTom40 (13–17) andmore recentlyMiro (10, 18–20). Ubiq-
uitination of Mfn1 leading to its proteasomal degradation may
act to sequester damaged mitochondria, whereas ubiquitina-
tion of substrates, including VDAC1, is proposed to initiate
HDAC6/p62/LC3-dependent autophagosome formation (13,
14, 21). Regulation of the Miro trafficking complex by PINK1
and Parkin may also be critical to block the transport of dam-
aged mitochondria, as removing Miro, the key adaptor that
couples mitochondria to the microtubule motor proteins,
could isolate the damaged organelles from the functional mito-
chondrial network (18). However, the mechanisms by which
PINK1 and Parkin target andmodifyMiro leading to its altered
function remain unclear. Moreover, how Parkin is anchored to
damaged mitochondria, the dynamics, and consequences of
Miro ubiquitination and degradation and whether Miro ubiq-
uitination is disrupted in PD related pathology also remain
poorly understood.
Here, we characterize in human dopaminergic SH-SY5Y
neuroblastoma cells the dynamics of Miro1 ubiquitination by
the PINK1/Parkin mitochondrial quality control system. We
find that mitochondrial damage triggers rapid (within tens of
minutes) and persistent PINK1 and Parkin-dependent Miro
ubiquitination, whereas Miro degradation has a much slower
onset (hours). Miro ubiquitin chains were found to be predom-
inantly lysine 27 (ubiquitin Lys-27)-mediated, in addition to
some Lys-11 and Lys-29, whereas we saw little Lys-48-linked
ubiquitination. In SH-SY5Y cells, Miro1 ubiquitination is pri-
marily dependent on Ser-65 within Parkin, a recently reported
serine residue at the N terminus of Parkin that is heavily phos-
phorylated by PINK1 (22). Moreover, we find this site plays an
important role in regulating Parkin function on the mitochon-
drion in cortical neurons. We also show that Miro turnover on
damaged mitochondria is altered in PD patient-derived fibro-
blasts containing a mutation in the PARK2 gene, suggesting
that correct regulation of Miro function may be disrupted in
PD. Our results provide new insights into the regulation of the
Miro-dependent mitochondrial transport machinery during
mitophagy and further suggest that disruption of this regula-
tion may be implicated in PD pathogenesis.
EXPERIMENTAL PROCEDURES
Constructs—cDNA constructs encoding mtDsRed2, GFPMiro1,
and mycMiro1 have been described previously (1, 5, 23). GFP-
Miro1 S156A and S156Emutations were made by site-directed
mutagenesis on theGFPMiro1 backbone; GFPTRAK1was cloned
by insertion of the mouse TRAK1 sequence in the EGFP-C1
vector. The following mutants were from Addgene: pMito-
LSSmKate2-N1 (large Stokes shift mKate2) (plasmid 31879
(24)); pRK5-Parkin-Myc (plasmid 17612 (25)); EYFP-Parkin
(plasmid 23955 (26)); pRK5-HA-ubiquitin (plasmid 17608
(27)); ubiquitin Lys-27 (plasmid 22902 (28)); Lys-29 (plasmid
22903 (28)); Lys-33 (plasmid 17607 (27)); Lys-48 (plasmid
17605 (27)); Lys-63 (plasmid 17606 (27)); K48R (plasmid 17604
(27)); and K29R (plasmid 17602 (27)). HAUbiquitin Lys-6, Lys-
11, K6R, K11R, K27R, and K27R/K29R mutants were made by
site-directedmutagenesis on the pRK5-HA-ubiquitin or on the
pRK5-HA-ubiquitin KO (plasmid 17603 (27)) backbone. YFP-
Parkin S65A and S65E mutations were made by site-directed
mutagenesis on the YFP-Parkin backbone. EGFP-C1 was from
Clontech. pcDNA4-PINK1-Myc was a gift from Hélène Plun-
Favreau, and pSC2-mCherry-Miro1 was a gift from John
Carroll.
Antibodies and Reagents—Anti-Miro1 (catalog no. HPA010687,
recognizing Miro1 and Miro2), anti-Miro2 (catalog no.
HPA012624), and anti-TRAK1 antibodies were from Atlas
(Miro1 1:1000 andMiro2 and TRAK1 1:500, rabbit); anti-Mfn1
and ApoTrackTM cytochrome c Apoptosis WB Antibody Mix-
ture (CV, PDH E1, cytochrome c, GAPDH) were from
Abcam (1:1000, mouse); anti-actin (1:2000, rabbit) and anti-
FLAG (1:1000, rabbit) were from Sigma; anti-Tom20 (1:500,
rabbit) was from Santa Cruz Biotechnology; anti-mono- and
polyubiquitinylated conjugates (FK2) was from Enzo Life Sci-
ences (1:1000, mouse); and anti-GFP antibody was from Neu-
romab (clone N86/8, 1:100, mouse) or Nacalai Tesque (1:2000,
rat). Anti-Myc (9E10) and anti-HA were obtained from 9E10
and 12CA5 hybridoma lines respectively and used as superna-
tant at 1:100. Secondary HRP-conjugated antibodies were pur-
chased from Rockland and used at 1:5000. Secondary antibod-
ies Alexa-488, Alexa-564, and Alexa-633 were purchased from
Invitrogen and used at 1:1000. Dylight-405 was from Jackson
ImmunoResearch and used at 1:500.
FCCP (Sigma), was used at 10 M; MG-132 (Cayman Chem-
ical) was used at 30 M for 30 min before and during FCCP
treatment; bafilomycin 1A (BioVitica) was used at 1 M for 30
min before and during FCCP treatment; valinomycin (Sigma)
was used at 2 M in Neurobasal medium (Invitrogen) supple-
mented with 0.6% D-glucose.
Cell Culture—FLAGParkin stably overexpressing SH-SY5Y
cells are a gift fromDr. Helen Ardley (Leeds Institute ofMolec-
ular Medicine) and were previously described (29). PINK1 and
nonsilencing shRNA stably expressing SH-SY5Y were previ-
ously described (30, 31). SH-SY5Y,COS-7,HeLa, andHEKcells
were maintained in Dulbecco’s modified Eagle’s medium
(DMEM, Invitrogen) supplemented with 10% heat-inactivated
FBS, penicillin, and streptomycin (2 g/ml puromycin was
added to the SHSY-5Y nonsilencing or PINK1 shRNA-overex-
pressing cellmedia as a selection antibiotic). Human fibroblasts
were derived frompunch biopsies takenwith informed consent
from a control patient or from a patient carrying a homozygous
deletion of exons 3 and 4 of the PARK2 gene. The ethics for this
study were approved by the London-City Road andHampstead
REC committee. The tissue was dissected, and fibroblasts were
cultured in DMEM supplemented with 10% heat-inactivated
FBS, penicillin, and streptomycin. Cells were kept in 5% CO2 at
37 °C, in a humidified incubator.
SH-SY5Y, HeLa, and HEK cells were transfected by nucleo-
fection (Amaxa, Lonza), and COS-7 cells were electroporated
using a Capacitance Extender II accessory module (Bio-Rad).
Experiments were carried out 48 h post-transfection unless
otherwise stated.
Neuronal cultures were prepared from E18 Sprague-Dawley
rat embryos of either sex. Briefly, hippocampi and cortices were
dissected from E18 embryos. Hippocampi were incubated in
0.125% trypsin and cortices in 0.25% trypsin for 15min at 37 °C.
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Neurons were then washed, triturated, and immediately plated
on 13-mmcoverslips coatedwith 500g/ml poly-L-lysine or on
plates coated with 50 g/ml poly-L-lysine and maintained in
Neurobasal plus B27 supplement (Invitrogen). Cortical neu-
rons were transfected by nucleofection before plating as
described previously (1, 32, 33), and hippocampal neuronswere
transfected with Lipofectamine 2000 (Invitrogen) at 10–12
days in vitro and analyzed at 13–15 days in vitro.
Biochemical Assays—For ubiquitination assays, cells were
lysed in RIPA buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1 mM
EDTA, 2 mM EGTA, 1% Nonidet P-40, 0.5% deoxycholic acid,
0.1% SDS, 1 mM PMSF, and antipain, leupeptin, pepstatin at 10
g/ml each). Lysateswere then incubated on a rotatingwheel at
4 °C for 1 h, and then nuclei and cellular debris were spun down
at 20,000  g for 10 min. Supernatants were incubated at 4 °C
for 2 h with 10 l of a 50% slurry of either GFP-TRAP beads
(Chromotek) or anti-Myc beads (Sigma). For endogenous
Miro1 immunopurification, 0.5 g of anti-Miro1 was added in
parallel with a nonimmune rabbit IgG control antibody for
1.5 h. Complexes were then precipitated for 1.5 h with 15 l of
50% protein A-Sepharose bead slurry (Generon). Bound mate-
rial was washed five times in the above buffer before elution
with 3 Laemmli sample buffer.
Coimmunoprecipitation experiments were carried out in a
similar way. Cells were lysed in 50 mM Tris, pH 7.4, 150 mM
NaCl, 1 mM EDTA, 0.5% Triton X-100, 1 mM PMSF, antipain,
leupeptin, and pepstatin at 10 g/ml each. After clearing the
lysates of nuclei and cellular debris, the samples were incubated
with GFP-TRAP beads; the immunoprecipitated complexes
were washed three times with the above buffer and eluted with
3 Laemmli sample buffer. Samples were thenwestern-blotted
on nitrocellulose (GE Healthcare), developed with Crescendo
substrate (Millipore), and detectedwith a LAS 4000 imager (GE
Healthcare). Densitometric quantification of bands on gels was
carried out using the software Quantity One (Bio-Rad).
Ub Chain Restriction (UbiCRest) Analysis—UbiCRest assays
were performed as described previously (34). Briefly, immuno-
purified GFPMiro1 was resuspended in 2 deubiquitinase
(DUB) reaction buffer (100 mM Tris, pH 7.4, 100 mM NaCl, 10
mMDTT);USP21,OTUD2, andOtulinwere diluted in 2DUB
dilution buffer (50mMTris, pH 7.4, 300mMNaCl, 20mMDTT)
and incubated for 10 min at RT. DUBs were then added to the
immunoprecipitated GFPMiro1 (on GFP-TRAP beads) and
incubated for 30 min at 37 °C. The reaction was stopped by the
addition of Laemmli sample buffer; samples were run on a
8–15% SDS-polyacrylamide gel and blotted on PVDF mem-
brane (Amersham Biosciences).
Fixed Imaging—For fixed imaging, cells grown on coverslips
werewashed in 1PBS and fixed in 4%paraformaldehyde solu-
tion (4% paraformaldehyde, 4% sucrose in 1 PBS, pH 7.0) for
15 min. After three further washes in 1 PBS, coverslips were
incubated for 10min in blocking solution (0.5%BSA, 10% horse
serum, 0.2% Triton X-100 in 1 PBS). Coverslips were then
incubated for 1 h with primary antibodies diluted in blocking
solution, washed five times in 1 PBS, and incubated with sec-
ondary antibodies. After a further five washes in 1 PBS cov-
erslips were mounted on glass slides using ProGold anti fade
reagent (Invitrogen) and later sealed with nail varnish.
Imaging was carried out using a Zeiss LSM 700 upright con-
focal microscope with a 63 oil-immersion lens with 1.4
numerical aperture. Images were digitally captured using ZEN
2010 software.
Image Processing—Images were processed in ImageJ or
Metamorph. For colocalization studies, images were takenwith
comparable Hi/Low ratio and then arbitrarily thresholded.
Integrated colocalization function (Metamorph) was used to
measure the colocalization. In neurons, Parkin and ubiquitin
translocation to mitochondria were scored manually on blinded
samples, using the Cell Counter plug-in for ImageJ.
Statistical Analysis—All data were obtained using cells from
at least three different preparations. The numbers of cells stud-
ied are given in the text or figure legends. Statistical significance
across groups was analyzed using one-way analysis of variance
and Dunnett’s post hoc test to compare the data groups with
their reference group or the Bonferroni’s post hoc test to com-
pare all data groups. Individual differences were assessed using
individual Student’s t tests. Data are shown as mean S.E.
RESULTS
PINK1 and Parkin Regulate the Loss of Miro1 and Miro2
upon Mitochondrial Damage in Human Dopaminergic Neuro-
blastoma Cells and Fibroblasts—To identify and further char-
acterize PINK1- and Parkin-mediated regulation of Miro pro-
teins in neuronal cells, human-derived dopaminergic SH-SY5Y
neuroblastoma cells, where Parkin has been previously shown
to undergo mitochondrial translocation upon mitochondrial
damage (13), were analyzed usingwestern blotting. Exposure of
SH-SY5Y cells to the mitochondrial uncoupler FCCP led to a
loss of endogenous Miro1/2 protein at its expected molecular
weight (detected with an anti-Miro1 antibody that cross-reacts
withMiro2, data not shown)within 2 h of FCCP treatment (Fig.
1, A, top panel, and B), similar to the loss of Miro1 previously
reported upon induction of mitochondrial damage in HEK and
HeLa cells (18, 19), whereas the mitochondrial matrix protein
PDHE1was unaffected. To further examine the role of Parkin
in this process, we evaluated the kinetics of Miro1/2 loss in
control SH-SY5Y cells compared with SH-SY5Y cells constitu-
tively overexpressing Parkin (Parkin OE) and that exhibit
enhanced mitophagy. A significant facilitation of Miro1/2 loss
upon FCCP-induced mitochondrial damage could be observed
in the Parkin OE cells compared with control (Fig. 1, A, bottom
panel, and B). To further determine whether there was a sub-
stantial difference in FCCP-induced loss ofMiro1 versusMiro2,
we tested the specific loss of Miro2 in Parkin OE cells using a
Miro2-specific antibody, which revealed that endogenous
Miro1 andMiro2 appear to be lost with similar kinetics (Fig. 1E,
n  3). PINK1 acts upstream of Parkin to recruit the ligase to
the OMM upon mitochondrial damage (35). To investigate
whether PINK1 was involved in damage-induced Miro loss,
we used previously characterized SH-SY5Y cells, expressing
PINK1 shRNA or a nonsilencing shRNA (30, 31). FCCP treat-
ment induced a decrease in Miro1/2 levels in nonsilencing
shRNA expressing SH-SY5Y cells transfected with YFPParkin;
however, this effect was inhibited in SH-SY5Y cells expressing
PINK1 RNAi and transfected with YFPParkin (Fig. 1, C and D).
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Wealsomonitored the stability of other components ofMiro
protein complexes, including theMiro-binding kinesin adaptor
TRAK1 (2, 36, 37) and the mitochondrial fusion GTPaseMfn1,
a key regulator ofmitochondrial dynamics, which also interacts
with Miro (38). FCCP-induced Mfn1 loss was observed to rap-
idly occur upon mitochondrial damage facilitated by Parkin
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FIGURE 1.Mitochondrial damage triggers PINK1/Parkin-dependentMiro1/2 degradation in a dopaminergic neuroblastoma cell line. A and B, control
SH-SY5Y cells or stably overexpressing FLAGParkin SH-SY5Y (FLAGParkin OE) cells were incubated with FCCP (10M) for the indicated time. A, FCCP time course
experiment indicating the loss of the outermembrane proteinsMiro1/2 andMfn1 but not of the trafficking adaptor TRAK1 or themitochondrialmatrix protein
PDH E1. Loss of Miro1/2 and Mfn1 is favored by Parkin overexpression. B, bar graph quantifying the FCCP-dependent loss of Miro1/2. Miro1/2 normalized
mean intensity in control SH-SY5Y cells at 1 h FCCP 0.67 0.12 S.E.; 2 h, 0.52 0.13 S.E.; 3 h, 0.52 0.12 S.E., and 6 h, 0.62 0.08 S.E.; n 6. Miro1/2 mean
intensity in FLAGParkin OE SH-SY5Y cells at 1 h FCCP 0.54 0.12 S.E.; 2 h, 0.24 0.04 S.E.; 3 h, 0.07 0.05; 6 h, 0.04 0.02 S.E.; n 3, *, p 0.05; **, p 0.01; ***,
p 0.001. C andD, SH-SY5Y cells stably expressing either nonsilencing (NS) shRNA or PINK1 shRNA and transfectedwith YFPParkin were treatedwith FCCP (10
M) for the indicated time points. C, representative western blot of a FCCP time course. Miro1/2 loss is inhibited by the specific knockdown of PINK1. D, bar
graphquantifying this effect.Miro1/2normalizedmean intensity in nonsilencing shRNAi at 1h FCCP, 0.500.15 S.E.; 2 h, FCCP0.370.16 S.E.; 3 h, FCCP0.39
0.20 S.E., and 6h, FCCP 0.31 0.12 S.E.;Miro1/2mean intensity in PINK1 shRNAi expressing cells at 1 h FCCP 0.84 0.22 S.E.; 2 h, FCCP 0.80 0.30 S.E.; 3 h, FCCP
0.78 0.30 S.E., and 6 h, FCCP 0.58 0.23 S.E.; n 4; significance is calculated comparing treated samples to control (0 h) *, p 0.05; **, p 0.01. E, SH-SY5Y
cells stably overexpressing FLAGParkin were treated with FCCP (10 M) for several time points. Miro1/2 and Miro2 show similar degradation kinetics, n 3. F,
FCCP treatment (10M) of human control fibroblasts triggers the loss ofMiro1/2 aswell asMfn1 (left panel); however, FCCP-inducedmitochondrial damage in
human fibroblasts derived from a PD patient carrying a deletion of exons 3 and 4 of the PARK2 gene does not cause loss of Miro1/2 or Mfn1 (right panel).
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overexpression and blocked by PINK1 knockdown similar to
previous reports (15, 39), although we did not observe a signif-
icant change in TRAK1 protein levels under these conditions
(Fig. 1, A and C).
To further investigate the impact onMiro regulation in path-
ological conditions, we also assessed by western blotting the
Parkin-dependent loss ofMiro1/2 uponmitochondrial damage
in human patient-derived fibroblasts carrying a homozygous
deletion of exons 3 and 4 of the PARK2 gene encoding Parkin.
Compared with control fibroblasts, where FCCP induced a loss
of Miro1/2 in Parkin-deficient fibroblasts, Miro1/2 levels
remained stable (Fig. 1F). Thus, Miro levels upon mitochon-
drial damage, in dopaminergic neuroblastoma cells and in
human fibroblasts, are controlled by the PINK1/Parkin path-
way. Moreover, the regulation of Miro levels is disrupted in
fibroblasts with impaired Parkin function derived from a
patient with PD.
Ubiquitination of Miro by a PINK1 and Parkin Complex
uponMitochondrial Damage—Our results support a key role
for the PINK1/Parkin pathway in regulating Miro levels
upon mitochondrial damage in human dopaminergic SH-
SY5Y cells and fibroblasts. In agreement with this, using
coimmunoprecipitation assays in Parkin OE SH-SY5Y cells
heterologously coexpressing GFP-tagged Miro1 (GFPMiro1)
with Myc-tagged PINK1 (PINK1myc), we could readily dem-
onstrate the interaction between Miro and PINK1, as
reported previously in HEK cells (18, 19, 40). Moreover, in
agreement with Parkin being recruited to the mitochondrial
membrane only uponmitochondrial damage, we found that the
formation of a complex betweenMiro and Parkin could also be
observed, but this was only detected upon FCCP-induced dam-
age (Fig. 2A).
The loss of Miro1/2 at its expected molecular weight upon
mitochondrial damage is likely due to Miro ubiquitination by
Parkin. Indeed, we observed a robust increase in the levels of
GFPMiro1 ubiquitination, which could be seen as a high molec-
ular weight smear in the GFPMiro1 immunoprecipitates, upon
1 h of FCCP treatment in COS-7 cells overexpressing Parkin
alone but not PINK1 alone. Coexpression of Parkin together
with PINK1 led to a further significant potentiation of GFP-
Miro1 ubiquitination (Fig. 2,B andC). GFPMiro1, and to a lesser
extent GFPMiro2 (data not shown), were also found to be
robustly ubiquitinated in SH-SY5Y cells upon mitochondrial
damage, whereas the Miro and kinesin adaptor TRAK1 exhib-
ited very little ubiquitination (Fig. 3A) in agreement with its
relatively stable expression during the FCCP damage time
course (Fig. 1). Importantly, FCCP-induced ubiquitination of
endogenous Miro1/2 could also be observed in neuroblastoma
cells overexpressing YFPParkin (Fig. 2D) and was dependent on
PINK1 because ubiquitination levels were greatly reduced in
dopaminergic SH-SY5Y cells expressing shRNA to PINK1
compared with nonsilencing shRNA-expressing cells (Fig. 2, E
and F). We also confirmed FCCP-induced ubiquitination of
endogenous Miro1/2 using antibodies to endogenous mono-
and polyubiquitin (Fig. 2G).
To test whether Miro1 ubiquitination could affect its ability
to interact with themitochondrial motor complex, we analyzed
Miro1 binding to the kinesin adaptor TRAK1 by coimmuno-
precipitation; however, in our conditions mitochondrial dam-
age (10 M FCCP, 1 h) does not affect this interaction (Fig. 3, B
and C).
Lys-27-type Ubiquitination of Miro by a PINK1 and Parkin
Complex in Dopaminergic Neuroblastoma Cells—Because the
linkage type of the ubiquitin chain can determine the cellular
outcome of ubiquitination (41), we explored which chain
type(s) were assembled by Parkin on Miro1. To this end, HA-
tagged ubiquitin mutants permissive for only one type of ubiq-
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uitin chain were expressed in Parkin OE SH-SY5Y cells. Strik-
ingly, immunopurification of endogenous Miro1/2 from these
cell lysates revealed a high level of Lys-27 ubiquitin linkage on
Miro1/2 (in addition to some Lys-11, Lys-29, and Lys-63 link-
ages, Fig. 4A). In contrast, little Lys-48 ubiquitination was
observed, and consistent with this, in cells expressing a ubiqui-
tin mutant where Lys-48 was mutated to arginine (K48R) to
block Lys-48 ubiquitination, there was still substantial Miro1
ubiquitination (Fig. 4B). This is consistent with previous
reports demonstrating accumulation of Lys-27-linked ubiqui-
tin chains on mitochondria after FCCP treatment and Lys-27
polyubiquitination of VDAC1 (13). Implication of Lys-27 link-
age was also confirmed by a reduction of Miro1/2 ubiquitina-
tion smear with K27R and K27R/K29R ubiquitin mutants (Fig.
4B). To further investigate Miro1 ubiquitin chain composition
without affecting the chain formation by introducing ubiquitin
mutants, we have used chain-specific DUBs in ubiquitin chain
restriction (UbiCRest) analysis (42). For this, immunoprecipi-
tated GFPMiro1 was incubated with several DUBs of distinct
specificities. USP21 is a highly active, ubiquitin-specific but
linkage-aspecific DUB (43). USP21 efficiently cleaves GFPMiro1
ubiquitin chains, generating unmodified GFPMiro1, mono-
ubiquitin, and a small amount of mono-ubiquitinated GFP-
Miro1 (Fig. 4C). This confirms that the HA-positive Miro1
smear is exclusively polyubiquitinated GFPMiro1.
An enzyme that specifically recognizes and cleaves Lys-27
linkages has not been identified to date. However, OTUD2
shows linkage preference for Lys-11, Lys-27, Lys-29, and Lys-33
linkages and is the only human ovarian tumor DUB cleaving
Lys-27 chains efficiently. Incubation of GFPMiro1 with increas-
ing concentrations of OTUD2 results in a progressive shorten-
ing of high molecular weight GFPMiro1 ubiquitination, partial
rescue of GFPMiro1 at its expected molecular weight, and the
formation ofHA-positive bands at 20 and 30 kDa (Fig. 4C, black
arrowheads), which are likely to be ubiquitin dimers or trimers.
The latter could be released frommixed linkage chains on GFP-
Miro1. In contrast, incubation of GFPMiro1 with the highly
active but Met-1/linear chain-specific DUB Otulin (44) does
not affect GFPMiro1 ubiquitination (Fig. 4C). This confirms that
GFPMiro1 comprises atypical polyubiquitin chain linkages,
likely Lys-27 chains in addition to some Lys-11 and Lys-29.
Kinetics of Miro Ubiquitination and Degradation—Ubiquiti-
nation of Miro could lead to its rapid loss from the OMM by
degradative pathways, or alternatively Miro could remain on
the mitochondrial membrane in a ubiquitinated form where it
may act in another ubiquitination-mediated process such as
signaling. To better understand the functional consequences of
Miro regulation by the PINK1/Parkin pathway, we further
investigated the kinetics of Miro1 ubiquitination, performing a
time course of FCCP-induced mitochondrial damage in do-
mycMiro1
IP myc:
GF
P TRA
K1
GFPTRAK1
FCCP: - + - +
mycMiro1
FLAGParkin
Actin
GFPTRAK1
FCCP: - + - +
- 67
- 115 kDa
- 45
- 42
- 67
- 115 kDa
INPUT:
C
O
-I
P 
G
FP
TR
A
K
1/
in
p
u
t 
G
FP
TR
A
K
1 
  
FCCP: - +
0
0.2
0.4
0.6
0.8
1
1.2
B
IP GFP:
FCCP:
GF
P TRA
K1
my
c Mir
o1
GF
P M
iro
1
GF
P TR
AK
1
- 115 kDa
- 115 
 ++  --
GFP
FLAGParkin
INPUT:
FCCP:
GF
P M
iro
1
GF
P TR
AK
1
- 115 kDa
- 50
- ++ -
(Ub)n
Miro1
GFP
A
C
FIGURE 3. Effect of mitochondrial damage on TRAK1 ubiquitination and its interaction with Miro1. A, ubiquitination assays performed in SH-SY5Y cells
stably overexpressing FLAGParkin and transfected with either GFPMiro1 or GFPTRAK1. FCCP treatment (10 M, 1 h) triggers little ubiquitination of TRAK1
comparedwithMiro1;n3.B, coimmunopurification assay showsnochange in the interactionbetweenmycMiro1 andGFPTRAK1uponmitochondrial damage.
C, quantification of this effect (co-IP TRAK1 with FCCP 0.94 0.11, compared to control 1); n 3. IP, immunoprecipitation.
Ubiquitination ofMiro Is Dependent on Parkin Ser-65
14574 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 289•NUMBER 21•MAY 23, 2014
 at U
CL Library Services on June 9, 2014
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
paminergic ParkinOE SH-SY5Y cells.We found that the kinetics
of the FCCP-dependent increase of ubiquitinated GFPMiro1
correlated closely with those of the loss of immunoprecipitated
GFPMiro1 at 100 kDa. FCCP-induced loss of unmodified GFP-
Miro1 at its expected molecular mass (100 kDa) could be seen
within as little as 20 min. In parallel, levels of ubiquitinated
(highmolecularweight smear) GFPMiro1 rapidly increasedwith
a similar time course and appeared to remain stable for at least
1 h.With slower kinetics, ubiquitinated GFPMiro1 then appears
to undergo degradation, which can be observed by a clear
decrease in the levels of ubiquitinated high molecular weight
smear GFPMiro1 within the 2nd h of FCCP treatment (Fig. 5, A
andC). This delayed degradation of the ubiquitinatedGFPMiro1
appears to be dependent on the activity of the proteasome. In
fact, the loss of ubiquitinated GFPMiro1 at later time points
could be blocked by proteasomal inhibition with MG-132, but
not by lysosomal inhibition with bafilomycin 1A (Fig. 5, A, B
and D).
To further investigate Miro stability on the OMM, we quan-
tified GFPMiro1 levels on the mitochondria using confocal
microscopy, normalizing levels of GFPMiro1 to the mitochon-
drial marker mito-LSS-mKate2. In agreement with our bio-
chemical results, we found that GFPMiro1 levels remained sta-
ble on the OMM for at least 60 min after induction of
mitochondrial damage with FCCP and well beyond the initial
fast ubiquitination, as can be observed by the relatively stable
levels of GFPMiro1 fluorescence signal. Only at later stages
(after 2 h) did GFPMiro1 fluorescence intensity begin to
decrease, correlating closely with the observed delayed degra-
dation of ubiquitinated Miro (Fig. 5, E and F). These results
demonstrate that in human dopaminergic neuroblastoma cells
Miro is initially rapidly ubiquitinated on the OMM where it
appears to remain in a ubiquitinated form before undergoing a
slower degradation and removal, dependent on proteasomal
activity.
Role of Miro and Parkin Phosphorylation in Regulating Miro
Ubiquitination and Degradation—Several reports have sug-
gested that phosphorylation of OMM proteins by PINK1 is a
critical step in the initiation of mitophagy. A previous report
showed that phosphorylation ofMiro1 on serine 156 by PINK1
was important for Parkin-mediated control ofMiro levels upon
mitochondrial damage in HEK and HeLa cells (18). We there-
fore investigated whether phosphorylation of Miro by PINK1
could similarly regulate the dynamics of its ubiquitination by
Parkin in dopaminergic SHSY-5Y cells. To address the role of
Miro1 phosphorylation for regulating the ubiquitination of
Miro in dopaminergic neuroblastoma cells, we tested the ability
of phospho-null (S156A) and phospho-mimetic (S156E)
mutants of Miro1 to be ubiquitinated upon mitochondrial
damage. In contrast to previous observationsmade in HEK and
HeLa cells (18), we found no major influence of this Miro1
phosphorylation site on Miro1 expression levels or ubiquitina-
tion levels upon mitochondrial damage in Parkin OE SH-SY5Y
cells (Fig. 6A, n  3). We further investigated the kinetics of
Miro1 ubiquitination upon a time course of FCCP-induced
mitochondrial damage in the Miro phospho-null (S156A)
mutant (Fig. 6B), but we found that in SH-SY5Y cells the phos-
pho-null mutant could undergo ubiquitination with kinetics
similar to that of wild type Miro (Fig. 6, B and C).
PINK1 was recently shown to directly phosphorylate Parkin
on serine 65 at the Parkin N terminus, which may serve to
activate Parkin (22). We therefore investigated the impact of
this critical PINK1 phosphorylation site in Parkin on Miro
ubiquitination levels upon FCCP-induced mitochondrial dam-
age in HeLa cells (which do not express endogenous Parkin
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(45)) or in SH-SY5Y cells (Fig. 6,D andE, respectively), express-
ing wild type Parkin or Parkin containing either phospho-null
or phospho-mimetic mutations at Ser-65 (S65A or S65E). In
contrast to the robust FCCP-induced ubiquitination of myc-
Miro1 observed in HeLa cells and SH-SY5Y cells expressing
wild type YFPParkin, Miro1 ubiquitination was greatly reduced
when YFPParkinS65A was expressed, supporting a key role for
PINK1-dependent phosphorylation of Parkin in Miro1 ubiq-
uitination. Interestingly, in cells expressing the S65E Parkin
mutant, Miro expression levels appeared substantially reduced
under basal conditions suggesting constitutive activity of the
phospho-mimetic S65E Parkinmutant to regulateMiro, poten-
tially due to impaired Ubl domain-mediated inhibition of the
ligase (Fig. 6,D andE) (46). In Parkin S65E-overexpressing cells,
mitochondrial damage induced some further Miro loss and
ubiquitination suggesting that additional regulatory mecha-
nisms may further contribute to mitochondrial damage-in-
duced activation of Parkin.
We also investigated whether the Ser-65 phospho-null and
phospho-mimetic Parkin mutants were recruited in a similar
D
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way to wild type Parkin to damagedmitochondria and whether
Miro had a role in regulating their translocation and stabiliza-
tion on the OMM. Following FCCP treatment, nearly 80% of
wild type Parkin was recruited to the damaged mitochondria,
labeled with the mitochondrial marker Tom20, of which
expression levels were not altered after 1 h of FCCP treatment
(Fig. 7E). However, we found that the S65A and S65E Parkin
mutants showed delayed recruitment dynamics. At early time
points (1 h), we found a significant reduction in the transloca-
tion of the S65A and S65E mutants onto mitochondria com-
pared with wild type Parkin (Fig. 7, A and B). However, 2 h after
mitochondrial damage, both mutants were found to be translo-
cated on the mitochondria to the same extent as wild type Parkin
(data not shown), indicating that the translocation of these Parkin
mutants was delayed compared with that of wild type Parkin as
recently reported (47). Interestingly,we found that overexpressing
wild typemCherryMiro1significantly increased therecruitmentand
stabilization of both the S65A and S65E mutants at early time
points (Fig. 7, C and D). This suggests that upon mitochondrial
damageMiro1may act as a component of a Parkin receptor com-
plex for activated Parkin on the OMM.
Impact of Parkin Ser-65 Mutants on Miro Degradation in Pri-
mary Neurons—Our results further support a critical role for
phosphorylation at Ser-65 in Parkin for regulating substrate ubiq-
uitination ofOMMproteins andmitophagy. To assessmitophagy
and investigate the role of the Ser-65 within Parkin in primary
neurons, rat hippocampal cells were transfected with YFPParkin
and HAubiquitin together with the mitochondrial marker
mtDsRed2. Mitochondrial damage triggered by valinomycin (2
M, 90 min), a mitochondrial uncoupling agent (potassium iono-
phore) that induces, in a similar fashion to FCCP, PINK1-depen-
dent Parkin phosphorylation (22), led to a robust translocation of
YFPParkin to mitochondria that correlates with an increased and
localized HAubiquitin signal on the organelles (Fig. 8,A–C).
A
B
GFPMiro1
FlagParkin
INPUT:
FCCP:
- 115 kDa
- 50
+++ ---
WT S156A S156E
INPUT:
GFPMiro1
FLAGParkin
Actin
FCCP:
IP GFP:
GFPMiro1
FCCP:
WT S156A
0 20 40 60 0 20 40 60 min
- 115
- 115 kDa
WT S156A
- 115 kDa
- 50
- 42
0 20 40 60 0 20 40 60 min
D
INPUT:
mycMiro1
YFPParkin
Actin
FCCP:
WT S65A S65E
- + - + - +
- 97 kDa
- 97
- 42
IP GFP:
GFPMiro1
WT S156A S156E
- 115 kDa
- 115
+++ ---FCCP:
(Ub)n Miro1
(Ub)n Miro1
IP myc:
mycMiro1
FCCP: - + - + - +
- 97 kDa
- 97 
WT S65A S65E
(Ub)n Miro1
0 20 40 60 minFCCP:
N
or
m
ai
ls
ed
 In
te
ns
ity
- 0.5
0
0.5
1
1.5
2
2.5 WT
S156A
C
WT ub
S156A ub
IP myc:
mycMiro1
(Ub)n Miro1
- 97 kDa
- 97 
WT S65ES65A
FCCP: - + - + - + - +
INPUT:
mycMiro1
YFPParkin
Actin
FCCP:
WT S65A S65E
- + - + - +
- 97 kDa
- 97
- 42
- +
E
FIGURE 6. Miro1 phosphorylation does not affect its ubiquitination dynamics, whereas Parkin phosphorylation does. A–C, GFPMiro1 phospho-null
(S156A) or phospho-mimetic (S156E) mutants show no difference in ubiquitination dynamics compared with wild typeMiro1 in Parkin OE SH-SY5Y cells; C, in
ubiquitinatedS156AMiro1mean intensity at 0min, 0.190.08; at 20min, 0.570.17; at 40min, 1.750.47; at 60min, 1.0, ubiquitinatedwild typeMiro1mean
intensity at 0 min, 0.04  0.004; at 20 min, 0.29  0.08; at 40 min, 0.96  0.22; at 60 min, 1.0; n  3. Data are shown as mean  S.E. D, expression of the
phospho-null YFPParkin S65Amutant in HeLa cells blocks FCCP-inducedmycMiro1 ubiquitination and its subsequent loss. Phospho-mimetic S65E Parkin allows
a residual Miro1 ubiquitination; n 3. E, same effect is observed in SH-SY5Y dopaminergic cells; n 1.
Ubiquitination ofMiro Is Dependent on Parkin Ser-65
MAY 23, 2014•VOLUME 289•NUMBER 21 JOURNAL OF BIOLOGICAL CHEMISTRY 14577
 at U
CL Library Services on June 9, 2014
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Finally, to further investigate the role of the Parkin Ser-65 site
in regulating substrate ubiquitination during mitophagy in pri-
mary neuronal cells, we performed biochemical experiments to
assessMiro1 loss in rat cortical neurons transfected with either
wild type YFPParkin or S65A and S65E Parkin mutants. In neu-
rons expressingwild type YFPParkin andmycMiro1, a robust loss
of Miro1 could be detected upon valinomycin-induced mito-
chondrial damage, similar to what we observed in SH-SY5Y
dopaminergic cells. In contrast, in neurons expressing S65A or
S65E Parkin mutants, we did not observe a significant damage-
induced decrease of Miro1 levels (Fig. 8D).
DISCUSSION
Here, we characterize in dopaminergic SH-SY5Y neuroblas-
toma cells, PD patient-derived fibroblasts, and primary rat neu-
rons the mitochondrial damage-induced turnover and ubiq-
uitination dynamics of the Miro mitochondrial trafficking
complex. We find that FCCP-induced mitochondrial damage
FIGURE 7.Miro1 facilitates the recruitment of Parkin S65AandS65E todamagedmitochondria.A, confocal images of HEK cells transfectedwithwild type
YFPParkin or S65A or S65E Parkin mutants and treated with 10 M FCCP for 1 h. Scale bar, 20 m. B, Parkin recruitment to the mitochondria is analyzed as
integrated colocalization of YFPParkin over the mitochondrial marker Tom20 and quantified in the bar graph. Percentage of wild type Parkin onmitochondria
is 78.19 4.86%; S65A Parkin is 33.27 1.46%; S65E Parkin is 52.97 4.68%; n 9–14, #, p 0.05; ###, p 0.005. * is used to indicate significance between
treated/untreated samples, whereas # is used to indicate significance within a treatment group, #, p 0.05, **, p 0.01; ###, ***p 0.005. Data are shown as
mean S.E.C,overexpressionofmCherryMiro1 togetherwith YFPParkin or the S65AandS65Emutants facilitates Parkin recruitment to themitochondria after 1 h
of FCCP treatment. Scale bar, 20 m. D, quantification of this effect. Percentage of wild type Parkin on mitochondria at 1 h when Miro1 is overexpressed at
61.69 2.55%; S65A Parkin is 63.55 5.24%; S65E Parkin is 72.82 4.85%; n 12–14, ***, p 0.005. Data are shown asmean S.E. E, western blot showing
that the mitochondrial marker Tom20 levels are not altered after 1 h of FCCP treatment (10 M).
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drives a robust loss of Miro at its expected molecular weight
dependent on PINK1 and Parkin, and this is disrupted in PD
patient-derived fibroblasts (lacking functional Parkin). Miro
loss correlates with its fast ubiquitination on theOMMwhere it
remains stably ubiquitinated prior to degradation. Using phos-
pho-mimetic and phospho-null mutants, we also find that
Ser-65 within Parkin, which is a substrate of PINK1-mediated
phosphorylation, acts as a key point of regulation of the path-
way. Moreover, we demonstrate the key role of the Parkin
Ser-65 residue for regulating mitochondrial damage-induced
ubiquitination of Miro1 in primary neurons.
Although our results are consistent with the PINK1/Parkin
pathway targetingMiro to block mitochondrial trafficking, our
results do not support a rapid, mitochondrial damage-induced
depletion of Miro from the OMM. The loss of Miro at its
expected molecular weight upon mitochondrial damage
reported here and in earlier reports (18, 19) is primarily due to
a shift from the expected molecular weight of Miro to higher
molecular weight species upon ubiquitination. Consistent with
this, we found that Miro1 was robustly ubiquitinated in do-
paminergic SH-SY5Y cells upon mitochondrial depolarization
similar to previous observations in HeLa cells and Drosophila
neurons (19). Our analysis of the kinetics of Miro ubiquitina-
tion does not, however, support a mechanism whereby Miro
ubiquitination leads to its fast degradation to underpin a rapid
uncoupling of mitochondria from the kinesin transport path-
way and the consequentmitochondrial arrest.Moreover, in our
system, the interaction betweenMiro1 and the kinesin adaptor
TRAK1 is not affected by mitochondrial damage. Rather, our
results suggest a model whereby Miro is initially rapidly ubiq-
uitinated on the OMMwhere it remains localized in a ubiquiti-
nated form for some considerable time prior to it being turned
over, dependent on the activity of the proteasome. This sug-
gests that Miro ubiquitination (rather than ubiquitination-in-
duced Miro degradation) may directly act as a rapid signal on
the OMM for mitochondrial arrest. A number of mechanisms
could underpin this. For example, ubiquitinated Miro could
mediate the recruitment of other factors such as p62 and/or
HDAC6 to the mitochondrial trafficking complex to facilitate
the clustering of damagedmitochondria prior to their clearance
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FIGURE8.Parkin is recruited todamagedmitochondria inneuronsanddeterminesMiro1 loss.A, confocal imagingof hippocampal neurons overexpress-
ing YFPParkin, HAubiquitin, and the mitochondrial marker mtDsRed2 shows that valinomycin (Val) treatment (2 M, 90 min) of the neuronal culture induces
Parkin translocation to mitochondria and ubiquitination of the organelles (arrowheads; scale bar, 20 or 5 m for the zoomed image). B and C, bar graphs
quantifying, respectively, Parkin recruitment and ubiquitin-positive mitochondria (6.83  0.63% of total mitochondria were Parkin-positive after 90 min of
valinomycin comparedwith 2.08 0.32%Parkin-positivemitochondriawithDMSO control; ***, p 0.001; 6.21 1.14%of totalmitochondriawere ubiquitin-
positive after 90min of valinomycin treatment, comparedwith 1.65 0.37%with DMSO control, **, p 0.005; n 3, 3 cells per n). Data are shown asmean
S.E.D,mitochondrial damage (valinomycin, 2M, 90min) triggers the loss of immunopurifiedmycMiro1 in cortical neurons overexpressingwild type Parkin but
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by mitophagy. Moreover, Miro ubiquitination may also either
directly or, by recruitment of HDAC6 and/or p62, sterically
hinder its association or functional interaction with microtu-
bule motor proteins leading to mitochondrial arrest.
We find Miro1 ubiquitination to include atypical Lys-27-
linked ubiquitin chains, which have so far only been observed in
connection with Parkin (13). It is interesting that modification
with this chain type does not seem to lead to Miro1 immediate
degradation, which is consistent with previous proteomic anal-
ysis showing that Lys-27 chains are not significantly enriched
when the proteasome is inhibited, in contrast to Lys-48 or
Lys-11 chains (48). This suggests that the chain type may have
other more specific roles such as mediating mitophagy. Inter-
estingly, Lys-27-linked polyubiquitin chains have previously
been correlated to p62 translocation to damagedmitochondria
(13).
We also provide new insights into the regulation of Miro
turnover and ubiquitination dynamics by PINK1-dependent
phosphorylation, which remains controversial. An initial
report demonstrated robust phosphorylation of Miro at Ser-
156 by PINK1 in vitro (18), although a more recent study was
unable to find phosphorylation of Miro in vitro or a substantial
role for the phosphorylation of these sites in the regulation of
Miro stability (19). In our experiments, we did not find that the
Miro1 Ser-156 phosphorylation site played a critical role in
Miro1 ubiquitination or turnover in dopaminergic SH-SY5Y
neuroblastoma cells. Although Miro phosphorylation by
PINK1 could impact the rate or kinetics of Miro ubiquitination
by Parkin, importantly, we did not find any substantial differ-
ence in the ubiquitination kinetics of phospho-null Miro1
S156A compared with wild typeMiro1. Thus, phosphorylation
ofMiro1 by PINK1 to regulateMiro stability and ubiquitination
may occur in a cell-specific manner or have a cell-specific
impact on Miro ubiquitination kinetics, depending on the
expression levels of Parkin or of other regulatory factors such as
Miro protein phosphatases. In agreement with our data, in a
recent screen of 16 putative PINK1 substrates (including
Miro2), only Parkinwas found to be robustly phosphorylated by
PINK1 in vitro (22).
In contrast, we found that Ser-65 in Parkin, recently reported
to be robustly phosphorylated by PINK1 (22, 47), played a crit-
ical role in regulating Miro ubiquitination levels. In both HeLa
cells and SH-SY5Y neuroblastoma cells, expression of phos-
pho-null S65A Parkin leads to substantially reduced Miro
ubiquination (although Parkin S65A was translocated onto the
mitochondria in these conditions) that correlates with an
increased stability of the protein. The S65E phospho-mimetic
Parkin had instead the opposite effect, apparently increasing
Miro turnover under basal conditions. A slight residual ubiq-
uitination of Miro1 could be detected when Parkin S65A was
expressed, suggesting that other E3 ubiquitin ligases could act
together with Parkin to ubiquitinateMiro.We also investigated
the role of Ser-65 in primary cultured neurons.We show that as
in HeLa cells and SH-SY5Y cells, Miro stability is regulated by
this key site within Parkin. Parkin activation is tightly tuned and
requires several levels of activation. Following recruitment to
damaged mitochondria, Parkin needs to be activated by phos-
phorylation on its Ser-65 residue. As recently suggested (22, 46,
47), modifying the charge of the Ubl domain of Parkin (by
mutagenesis or phosphorylation) could release its autoinhibi-
tion, favoring an active conformation of the E3 ubiquitin ligase.
S65E Parkin mutant could therefore more easily interact with
and modify its substrates leading to their increased turnover
and decreased steady state levels.
Interestingly, we also found that Miro levels on the mito-
chondria could stabilize the phospho-null (S65A) and phos-
pho-mimetic (S65E) versions of Parkin on the mitochondria in
HEK cells. These results suggest that the levels of Miro (and
potentially other OMMParkin substrates as recently suggested
for Mfn2 (49)) may play an additional role in stabilizing Parkin
on the OMM. This would suggest that substrate binding by
Parkin in conjunction with its phosphorylation could act
together to stabilize Parkin on the OMM, providing a mecha-
nism to tune Parkin levels to that of substrates on the OMM.
These findings provide an in depth analysis ofMiro1 dynam-
ics following mitochondrial damage highlighting its implica-
tion in mitophagy. Moreover, we uncover a role of Miro as part
of the Parkin receptor complex on the OMM and its potential
role in tuning Parkin-mediated mitochondrial quality control.
Our data corroborate an important role of Lys-27-linked poly-
ubiquitin in this process. We also disclose the importance of
Ser-65 within Parkin as a regulator of its function and stability
on damaged mitochondria. This may open new strategies to
target mitochondrial dysfunction in PD pathogenesis.
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